Predict your next investment

Corporation
SOFTWARE (NON-INTERNET/MOBILE) | Healthcare Software
simbionix.com

See what CB Insights has to offer

Founded Year

1997

Stage

Acquired - II | Acquired

Total Raised

$12M

Valuation

$0000 

Revenue

$0000 

About Simbionix

Simbionix is a provider of 3D simulation and training products for medical professionals and the healthcare industry. The company is committed to delivering the highest quality products, advancing clinical performance, and optimizing procedural outcomes.On July 28, 2021, Simbionix was acquired by Surgical Science at a valuation of $305M.

Simbionix Headquarter Location

Beit Golan Corner of Golan and Hanegev St.

Airport City, 70151,

Israel

+972-3-9114444

Latest Simbionix News

3D Systems Sells Medical Simulation Business to Surgical Science Sweden

Aug 6, 2021

3D Systems Sells Medical Simulation Business to Surgical Science Sweden 3D Systems Sells Medical Simulation Business to Surgical Science Sweden Will focus exclusively on its strategic purpose of enabling additive manufacturing solutions for applications in growing markets. 3D Systems expects completion of the Simbionix transaction to occur in August 2021. Image courtesy of 3D Systems. 3D Systems08.06.21 3D Systems today announced it has signed a definitive agreement to sell its medical simulation business, Simbionix, to Surgical Science Sweden AB , a leading supplier of virtual reality simulators for medical training, for a purchase price of $305 million, subject to customary closing conditions and adjustments. This action will complete 3D Systems’ initiative to divest non-core businesses in order to focus exclusively on its strategic purpose as the leader in enabling additive manufacturing solutions for applications in growing markets that demand high-reliability products. “Over the last several months, 3D Systems has divested a number of assets that are not core to our industry-leading additive manufacturing solutions business,” said Dr. Jeffrey Graves, president & CEO, 3D Systems. “The final of these is our Simbionix business, under the leadership of Ran Bronstein, which has secured a strong position in the medical simulation, training and robotic surgery market. As the Simbionix team now joins forces with Surgical Science, I believe their future will be even brighter, with increased scale and an ability to leverage the core strengths of both businesses in a growing medical simulation market.” Dr. Graves continued, “The proceeds from this sale, combined with previously announced divestitures, will leave us in a strong position, with a cash balance of approximately $500 million and no debt. Having reorganized the company into two business units - Healthcare and Industrial Solutions - and restructured to drive operational efficiencies over the last year, we now move forward expecting strong organic growth and profitability, at both a gross margin and EBITDA margin level, and positive operating cash flow capable of sustaining the investments needed to meet increasing customer demand for additive technology. With our scale, our industry-leading breadth of technology, which spans polymer and metal solutions, and an applications focus that is proving successful in accelerating customer adoption of additive manufacturing, we are very well positioned to remain a leader in the additive manufacturing industry.”   Earlier this year 3D Systems announced initial investments to bolster its leadership position with the acquisition of Allevi, Inc. and Additive Works to build its bioprinting and software portfolios, respectively. It has also announced planned expansions of its facilities in Rock Hill, South Carolina and Littleton, Colorado to address rising customer demand for additive manufacturing technologies. Additionally, the company recently expanded its technology leadership team by welcoming Dr. David Leigh as its new Chief Technology Officer for Additive Manufacturing to expand and accelerate application development and product innovation including all hardware, software, and materials development for production-scale additive manufacturing solutions. Dr. Leigh’s arrival has enabled 3D Systems’ co-founder, Chuck Hull, to increase his emphasis on biotechnology as Chief Technology Officer for Regenerative Medicine, leading the development of solutions that are creating exciting new opportunities in regenerative medicine. Through this transaction, Simbionix will be integrated with Surgical Science to form a market-leading company in the simulation of medical procedures, including advanced robotic surgery. Simbionix complements and strengthens Surgical Science’s position with a broad portfolio of simulators in areas such as general surgery, endovascular procedures, endoscopy, urology, orthopedics, ultrasound, and robotic surgery. Simbionix also brings long-established collaborations with leading medical technology companies and academic institutions that are at the forefront of developing new robotic surgery technology and operating procedures. Simbionix reported sales in 2020 of $40.8 million. 3D Systems expects completion of the Simbionix transaction to occur in August 2021. Related Breaking News Heart Rhythm Society 08.06.21 Armor Bionics 08.06.21 LifeSignals Inc. 08.05.21 Heart Rhythm Society 08.05.21 ASTM International 08.05.21 Royal Philips 08.05.21 Heart Rhythm Society 08.05.21 08.04.21 PR Newswire 08.04.21 PR Newswire 08.04.21 Evonik 08.04.21 Business Wire 08.04.21 Business Wire 08.04.21 PR Newswire 08.04.21 PR Newswire 08.04.21

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Simbionix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Simbionix is included in 2 Expert Collections, including 3D Printing.

3

3D Printing

594 items

Companies working in additive manufacturing and non-traditional, customization fabrication.

D

Digital Health

11,292 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Simbionix Patents

Simbionix has filed 18 patents.

The 3 most popular patent topics include:

  • Augmented reality
  • Mixed reality
  • Virtual reality
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/22/2017

1/5/2021

Image processing, Computer printing, 3D printing, Fused filament fabrication, 3D imaging

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/22/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

1/5/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Image processing, Computer printing, 3D printing, Fused filament fabrication, 3D imaging

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.